Hereditary hemochromatosis gene (HFE) variants are associated with birth weight and childhood leukemia risk

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1242-1248

  Dorak, M Tevfik ^a   Mackay, Rachel K ^a   Relton, Caroline L ^b   Worwood, Mark ^c   Parker, Louise ^d   Hall, Andrew G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d IWK HEALTH CENTRE   (Canada)

Author keywords

Birth weight; Genetic epidemiology; Genetic predisposition to childhood leukemia; HFE gene; Iron metabolism; Sex effect

Indexed keywords

HFE PROTEIN; IRON; ANTIMICROBIAL CATIONIC PEPTIDE; CD71 ANTIGEN; HEPCIDIN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; TRANSFERRIN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BIRTH WEIGHT; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENOTYPE; HEMOCHROMATOSIS; HUMAN; INFANT; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; ADOLESCENT; ADULT; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; CHILD; FETUS BLOOD; GENETIC PREDISPOSITION; GENETICS; LOW BIRTH WEIGHT; METABOLISM; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PRESCHOOL CHILD; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIMICROBIAL CATIONIC PEPTIDES; BIRTH WEIGHT; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; FETAL BLOOD; GENETIC PREDISPOSITION TO DISEASE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; IRON; MALE; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREGNANCY; PREGNANCY COMPLICATIONS; RECEPTORS, TRANSFERRIN; RISK; SEX FACTORS;

EID: 70449711286     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22236     Document Type: Article

References (48)

1. Ross JA. High birthweight and cancer: Evidence and implications. Cancer Epidemiol Biomarkers Prev 2006;15:1-2.
2. Dorak MT, Hammal DM, Pearce MS, et al. Examination of gender effect in birth weight and miscarriage associations with childhood cancer. Cancer Causes Control 2007;18:219-228.
3. Dorak MT, Sproul AM, Gibson BE, et al. The C282Y mutation of HFE is another male-specific risk factor for childhood ALL. Blood 1999;94:3957-3958.
4. Kallianpur AR, Hall LD, Yadav M, et al. Increased prevalence of the HFE C282Y hemochromatosis allele in women with breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:205-212.
5. Dorak MT, Burnett AK, Worwood M. HFE gene mutations in susceptibility to childhood leukemia: HuGE review. Genet Med 2005;7:159-168.
6. Dorak MT. HFE H63D variant and leukemia susceptibility. Leuk Lymphoma 2006;47:2269-2270.
7. Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-7421.
8. Stevens RG, Jones DY, Micozzi MS, et al. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047-1052.
9. Stevens RG, Graubard BI, Micozzi MS, et al. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-369.
10. Wu T, Sempos CT, Freudenheim JL, et al. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004;14:195-201.
11. Mainous AG III, Wells BJ, Koopman RJ, et al. Iron, lipids, and risk of cancer in the Framingham offspring cohort. Am J Epidemiol 2005;161:1115-1122.
12. Huang X. Iron overload and its association with cancer risk in humans: Evidence for iron as a carcinogenic metal. Mutat Res 2003;533:153-171.
13. Bergeron RJ. Iron:Acontrolling nutrient in proliferative processes. Trends Biochem Sci 1986;11:133-136.
14. Trowbridge IS, Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci USA 1982;79:1175-1179.
15. Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002;1603:31-46.
16. Smith SR, Ghosh MC, Ollivierre-Wilson H, et al. Complete loss of iron regulatory proteins 1 and 2 prevents viability of murine zygotes beyond the blastocyst stage of embryonic development. Blood Cells Mol Dis 2006;36:283-287.
17. Levy JE, Jin O, Fujiwara Y, et al. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet 1999;21:396-399.
18. Cogswell ME, Parvanta I, Ickes L, et al. Iron supplementation during pregnancy, anemia, and birth weight: A randomized controlled trial. Am J Clin Nutr 2003;78:773-781.
19. Siega-Riz AM, Hartzema AG, Turnbull C, et al. The effects of prophylactic iron given in prenatal supplements on iron status and birth outcomes: A randomized controlled trial. Am J Obstet Gynecol 2006;194:512-519.
20. Chase DS, Tawn EJ, Parker L, et al. The North Cumbria Community Genetics Project. J Med Genet 1998;35:413-416.
21. Toomajian C, Kreitman M. Sequence variation and haplotype structure at the human HFE locus. Genetics 2002;161:1609-1623.
22. Tsai HJ, Kho JY, Shaikh N, et al. Admixture-matched case-control study: A practical approach for genetic association studies in admixed populations. Hum Genet 2006;118:626-639.
23. Worwood M. Iron-deficiency anaemia and iron overload. In: Lewis SM, Bain BJ, Bates I, editors. Practical haematology, 10th edition. Philadelphia, PA: Elsevier; 2005.
24. Jackson HA, Carter K, Darke C, et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 2001;114:474-484.
25. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, et al. Geography of HFE C282Y and H63D mutations. Genet Test 2000;4:183-198.
26. Kemna EH, Tjalsma H, Willems HL, et al. Hepcidin: From discovery to differential diagnosis. Haematologica 2008;93:90-97.
27. Bulaj ZJ, Griffen LM, Jorde LB, et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996;335:1799-1805.
28. Srivastava S, Mehrotra PK, Srivastava SP, et al. Some essential elements in maternal and cord blood in relation to birth weight and gestational age of the baby. Biol Trace Elem Res 2002;86:97-105.
29. Mittwoch U. Blastocysts prepare for the race to be male. Hum Reprod 1993;8:1550-1555.
30. Kochhar HP, Peippo J, King WA. Sex related embryo development. Theriogenology 2001;55:3-14.
31. Wong CT, Saha N. Inter-relationships of storage iron in the mother, the placenta and the newborn. Acta Obstet Gynecol Scand 1990;69:613-616.
32. O'Brien KO, Zavaleta N, Abrams SA, et al. Maternal iron status influences iron transfer to the fetus during the third trimester of pregnancy. Am J Clin Nutr 2003;77:924-930.
33. Gambling L, Danzeisen R, Gair S, et al. Effect of iron deficiency on placental transfer of iron and expression of iron transport proteins in vivo and in vitro. Biochem J 2001;356:883-889.
34. Tamura T, Hou J, Goldenberg RL, et al. Gender difference in cord serum ferritin concentrations. Biol Neonate 1999;75:343-349.
35. Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004;39:21-29.
36. Lee SY, Patton SM, Henderson RJ, et al. Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE. FASEB J 2007;21:564-576.
37. Gloria-Bottini F, Lucarini N, La Torre M, et al. Birth weight and parental PGM1 alleles. Am J Hum Biol 2001;13:417-420.
38. Amante A, Gloria-Bottini F, Bottini E. Intrauterine growth: Association with acid phosphatase genetic polymorphism. J Perinat Med 1990;18:275-282.
39. Gloria-Bottini F, Bottini N, Cosmi E, et al. The effect of gender and ACP1 genetic polymorphism on the correlation between birth weight and placental weight. Placenta 2005;26:846-848.
40. Parkkila S, Waheed A, Britton RS, et al. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA 1997;94:13198-13202.
41. Gruper Y, Bar J, Bacharach E, et al. Transferrin receptor colocalizes and interacts with the hemochromatosis factor (HFE) and the divalent metal transporter-1 (DMT1) in trophoblast cells. J Cell Physiol 2005;204:901-912.
42. Beckman LE, Van Landeghem GF, Sikstrom C, et al. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis 1999;20:1231-1233.
43. Labuda D, Krajinovic M, Sabbagh A, et al. Parental genotypes in the risk of a complex disease. Am J Hum Genet 2002;71:193-197.
44. Datz C, Haas T, Rinner H, et al. Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: A protective role against iron deficiency? Clin Chem 1998;44:2429-2432.
45. Preziosi P, Prual A, Galan P, et al. Effect of iron supplementation on the iron status of pregnant women: Consequences for newborns. Am J Clin Nutr 1997;66:1178-1182.
46. Scholl TO. Iron status during pregnancy: Setting the stage for mother and infant. Am J Clin Nutr 2005;81:1218S-1222S.
47. Ahlgren M, Wohlfahrt J, Olsen LW, et al. Birth weight and risk of cancer. Cancer 2007;110:412-419.
48. Silva Idos S, De Stavola B, McCormack V. Birth size and breast cancer risk: Re-analysis of individual participant data from 32 studies. PLoS Med 2008;5:e193.